PRESS RELEASE:                Proof of Concept Programme  Awarded Proposals of 3rd Round

PRESS RELEASE: Proof of Concept Programme Awarded Proposals of 3rd Round

The 3rd Round of the Proof of Concept (PoC) was successfully completed after a creative 2-day evaluation of the Advisory Board at the Patras Science Park premises. 24 Proposals were submitted from all over Greece, with high scientific background, great extroversion and potential of commercial exploitation.

Advisory Board’s task assured by 51 Evaluators (among 84 registered in PoC database) in the evaluation of the proposals, coming from research centres, universities and the productive sector both from Greece and abroad. 

The evaluation of the Advisory Board was carried out by specialized executives of the European Union and Israel. The Advisory Board selected to meet via teleconference 4 pre-selected proposals separately. The awarded proposals which will be funded up to 50.000 euros, are the following 2:

1. PoC proposal: EVENOR – injury prevention for high performing athletes leveraging state of the art bio Mechanical methods and models
Applicant’s Full name:
Sofia Pomakidou
Host Organization Name: MEDINEVO IKE
City: Thessaloniki


Bioengineering science combines Mechanics, Medicine, Programming and Mathematics and studies the mechanical response of human body after the exposure to physical loads. In order to manage and predict myoskeletal failures, an innovative bioengineering method is proposed – EVENOR.

Despite the enormous investments, sports injuries rank among the major public health problems and cost millions. Nearly 70% of total injuries are non-contact (wear) so they can be predicted. Addressing the above challenge, Evenor offers a Biomechanical diagnostic test for high-stressed athletes who often experience muscle breaks. The purpose of the test is to prevent injuries and facilitate the rehabilitation process. The accompanying Evenor software product assists experts (Physicians) to predict injuries in athletes with high accuracy, providing information such as 3D visualization, topology, quantity and quality for failure areas, situation frame (snapshot) of every athlete individually.

The process is very simple: teams or physicians send email with MRI or Ultrasound copies; Evenor analyzes data and sends back results in terms of detailed reports.

Our chief objectives for this project are:

  • Extend the current version of our models (mechanical, mathematical) to address muscles involved in 4 common sports injuries – ACL, PCL, Quadriceps, Achilles Tendon).
  • Improve our protocol to analyse and extract more data from MRI/Ultrasound.
  • Validate the Evenor prototype product in a Use Case with a Super League football team.

Our primary market includes athletes, sports clubs, academies and sports clinics. Evenor will be offered to the international market by the Greek startup MEDINEVO. Our motto “In-game, not in pain” goes along with our vision of helping athletes remain healthy. Company’s goal is to become the world’s first injury prevention company based on Sports biomechanics.

2. PoC proposal: PhosPrint: an advanced Laser BioPrinting Technology for Regenerative Medicine applications
Applicant’s Full name: Symeon Papazoglou
Host Organization Name: PhosPrint Private Company
City: Athens


PhosPrint P.C. was founded in 2019 as a spin-off of the Institute of Communication and Computer Systems of the National Technical University of Athens (ICCS/NTUA) and is established at the Lefkippos Technology Park.

Our product is a semi-autonomous, laser bioprinting system dedicated to the high-resolution and high-precision printing of cells, biomolecules and drugs.  Our laser printer is unique as it is the first compact, desk top laser bioprinter at prototype TRL level 6 (Technology Readiness Level). Two upside opportunities are the production of 3D printing products and licensing agreements of the technology for bioreagents and cells.

We have a priority PCT in the filing of related applications [“Dual beam laser transfer”, Ioanna Zergioti, Symeon Papazoglou, PCT/EP2017/084740, 28/12/2017], and the freedom to operate in the Laser-Induced Bioprinting (LIB) process with our unique Dual Laser Induced Bioprinting (D-LIB).

Laser bioprinting is currently under development for the creation of tissues and organs suitable for regeneration and drug screening, eventually aiming to cure untreatable medical conditions, impacting the lives of millions while decreasing health care costs. Out of the bioprinting methods used, laser bioprinting achieves the highest degree of precision and resolution of printed structures offering a significant advantage for the printing of biomaterials.  Our targeted market is the Laser Segment of the Global Healthcare 3D Printing market, focusing on the subsegment for surgery units with applications in tissue regeneration. The Laser Segment is estimated at 25% of the total Healthcare 3D Printing market and valued at USD 239 Mn in 2017; it is expected to reach USD 780 Mn by 2025.

We would like to thank everyone for your participation to the program! We wish you Merry Christmas and a Creative New year!

Close Menu